|
gptkbp:instanceOf
|
gptkb:antiviral_drug
gptkb:protease_inhibitor
|
|
gptkbp:approvalYear
|
1995
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AE01
|
|
gptkbp:bioavailability
|
4% (without ritonavir)
|
|
gptkbp:brand
|
gptkb:Invirase
gptkb:Fortovase
|
|
gptkbp:CASNumber
|
127779-20-8
|
|
gptkbp:category
|
gptkb:antiretroviral_therapy
gptkb:HIV_protease_inhibitor
peptidomimetic
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to saquinavir
|
|
gptkbp:developedBy
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:drugInteraction
|
gptkb:rifampin
gptkb:ritonavir
gptkb:St._John's_wort
|
|
gptkbp:eliminationHalfLife
|
1-2 hours
|
|
gptkbp:firstBook
|
gptkb:HIV_protease_inhibitor
|
|
gptkbp:form
|
gptkb:tablet
capsule
|
|
gptkbp:hasMolecularFormula
|
C38H50N6O5
|
|
gptkbp:KEGGID
|
gptkb:D00744
|
|
gptkbp:legalStatus
|
prescription only
off-patent
|
|
gptkbp:mechanismOfAction
|
inhibits HIV-1 and HIV-2 protease
|
|
gptkbp:MedlinePlusID
|
a696028
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
670.84 g/mol
|
|
gptkbp:partOf
|
gptkb:HAART
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL646
gptkb:DB01232
390006
441243
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:lipodystrophy
nausea
diarrhea
abdominal pain
headache
|
|
gptkbp:synonym
|
gptkb:Ro_31-8959
gptkb:SQV
|
|
gptkbp:UNII
|
6CD2Q4430G
|
|
gptkbp:usedFor
|
gptkb:AIDS
HIV infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:J05AE
gptkb:SQV
|
|
gptkbp:bfsLayer
|
8
|
|
http://www.w3.org/2000/01/rdf-schema#label
|
Saquinavir
|